Meningococcal vaccines: From polysaccharide to conjugate vaccines;Vaccins anti-méningococciques: Des vaccins polysaccharidiques aux vaccins conjugués

Archives de Pediatrie

Volumn 19, Issue SUPPL.2, 2012, Pages

  Cohen, R ^a,b,c   Levy, C ^a,b  

^a ACTIV   (France)

^b GPIP Groupe de Pathologie Infectieuse Pédiatrique   (France)

^c CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCAL C CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; UNCLASSIFIED DRUG;

ARTICLE; DRUG EFFICACY; HIGH RISK PATIENT; HUMAN; IMMUNOLOGIC HYPO RESPONSIVENESS; IMMUNOPATHOLOGY; INFECTION PREVENTION; MENINGOCOCCEMIA; RISK ASSESSMENT; VACCINATION;

FRANCE; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; NEISSERIA MENINGITIDIS, SEROGROUP A; NEISSERIA MENINGITIDIS, SEROGROUP B; NEISSERIA MENINGITIDIS, SEROGROUP C; NEISSERIA MENINGITIDIS, SEROGROUP W-135; NEISSERIA MENINGITIDIS, SEROGROUP Y; POLYSACCHARIDES; RISK; TRAVEL; VACCINES, CONJUGATE; WORLD HEALTH;

EID: 84864966851     PISSN: 0929693X     EISSN: 1769664X     Source Type: Journal    
DOI: 10.1016/S0929-693X(12)71275-7     Document Type: Article

References (12)

1. Granoff D., Harrisson L., Borrow R. Meningococcal vaccines. Vaccines 2008, 399-434. Ed Saunders-Elsevier, 2008. 5 th. S. Plotkin, W. Orenstein, P. Offit (Eds.).
2. Parent du Châtelet I., Taha M.K., Lepoutre A., et al. Les infections invasives à méningocoque en France en. Bull Epidemiol Hebd 2011 2010, 45-46.
3. Granoff D.M., Pollard A.J. Reconsideration of the use of meningococcal polysaccharide vaccine. Pediatr Infect Dis J 2007, 26:716-722.
4. Siegrist C.A. Vaccine immunology. Vaccines 2008, 17-36. Ed Saunders-Elsevier, 2008. 5 th. S. Plotkin, W. Orenstein, P. Offit (Eds.).
5. Campbell H., Borrow R., Salisbury D., et al. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine 2009, 27(Suppl 2):B20-B29.
6. Trotter C.L., Andrews N.J., Kaczmarski E.B., et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004, 364:365-367.
7. Borrow R., Goldblatt D., Andrews N., et al. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdom. J Infect Dis 2002, 186:1353-1357.
8. Maiden M.C., Ibarz-Pavon A.B., Urwin R., et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008, 197:737-743.
9. Gaudelus J., Cohen R., Lepetit H., et al. Vaccinoscopie: couverture vaccinale vis-à-vis du méningocoque C. Medecine & Enfance 2011, 21:205-208.
10. Menvéo: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001095/WC500090150.pdf.
11. Osterga ard L., Silfverdal S.A., Berglund J., et al. A tetravalent meningococcal serogroups A, C W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix ((R)) in subjects aged 11-17 years: an open, randomised, controlled trial. Vaccine 2012, 30:774-783.
12. Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices (ACIP). Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease. Morb Mortal Wkly Rep 2011;60:1018-9.